Radiation Exposure News and Research

RSS

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009

Hansen Medical to exhibit its Lynx Robotic Ablation Catheter at the workshop on Cardiac Arrhythmias

Hansen Medical, Inc. will showcase its new Lynx Robotic Ablation Catheter for the first time at Venice Arrhythmias 2009, the 11th International Workshop on Cardiac Arrhythmias, Oct. 4-7, in Venice, Italy. The Lynx catheter is a small, flexible irrigated ablation catheter for customers in Europe to offer stability during the treatment of Atrial Fibrillation (AF).

5 Oct 2009

KYPHON Cement Delivery System from Medtronic

Medtronic, Inc. (NYSE:MDT), today announced the full U.S. launch of the KYPHON Cement Delivery System (CDS), adding an innovative bone cement delivery option to its extensive KYPHON Balloon Kyphoplasty product portfolio for the treatment of vertebral compression fractures (VCFs).

22 Sep 2009

Moses Cone Health System installs TomoTherapy cancer treatment system

TomoTherapy Incorporated announced today that Moses Cone Health System has installed North Carolina's first TomoTherapy® cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C.

22 Sep 2009

ECG gating reduces patient radiation dose during CT angiography

...

21 Sep 2009

Positron to promote its Attrius cardiac optimized PET scanner at the MedAxiom Fall Conference

Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will attend MedAxiom’s Fall Conference in Dana Point, California September 23rd, 2009 to promote their cardiac optimized PET scanner, the Attrius™ (www.medaxiom.com).

19 Sep 2009

Research study conducted to understand radiation-induced bone loss

A research project looking for ways to reduce bone loss in astronauts may yield methods of improving the bone health of cancer patients undergoing radiation treatment.

16 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

FDA clears Hansen Medical's Sensei X Robotic Catheter System

Furthering the medical robotic frontier in electrophysiology (EP), Hansen Medical, Inc. (NASDAQ: HNSN) today announced it has received U.S. Food & Drug Administration (FDA) clearance for its next generation Sensei® X Robotic Catheter System and it introduced the Artisan Extend™ Control Catheter. The company also introduced the Lynx™ Robotic Ablation Catheter, a small, flexible irrigated ablation catheter for customers in Europe.

16 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Edward Hospital announced today that it has established the Edward Neurosciences Institute in affiliation with the Northwestern Medical Faculty Foundation to bring the highest level of stroke care in the world to the west and southwest suburbs of Chicago.

11 Sep 2009

TomoTherapy signs purchasing agreement with GNYHA Services

TomoTherapy Incorporated, maker of the TomoTherapy® treatment system for advanced, CT-guided radiation therapy, announced today that it has signed an equipment supply group purchasing agreement with GNYHA Services, Inc. Pursuant to this agreement, TomoTherapy technology will be made available at contracted rates to more than 220 member hospitals in New York, New Jersey, Pennsylvania and Puerto Rico.

11 Sep 2009

AOLS to initiate clinical study for testing the efficacy of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that it has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates.

9 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009

CT screening for coronary artery calcification can cause radiation-induced cancer

A study based on computer modeling of radiation risk suggests that widespread screening for the buildup of calcium in the arteries using computed tomography scans would lead to an estimated 42 additional radiation-induced cancer cases per 100,000 men and 62 cases per 100,000 women, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

2 Sep 2009

Daytime surgeries reduce minor complication rates

Patients who have after-hour orthopaedic surgeries risk a slightly higher rate of necessary follow-up surgeries, according to a study published in the September 2009 issue of The Journal of Bone and Joint Surgery (JBJS). The data also suggests that patients whose surgeries took place during the day have the same healing, recovery time, and major complication rates as patients who have surgery after hours.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

American Imaging Management discusses about diagnostic imaging in a journal

American Imaging Management(R) (AIM), an operating subsidiary of WellPoint, Inc. and one of the leading companies in the radiology benefit management industry, today commended articles on diagnostic imaging that appear in the August 27, 2009 issue of the New England Journal of Medicine.

1 Sep 2009

CT and PET scans carry a very real risk of radiation exposure

Thomas Dehn, M.D., FACR, executive vice president and chief medical officer of National Imaging Associates, a Magellan Health Services (Nasdaq: MGLN) company, today issued the following statement about the New England Journal of Medicine study published on Aug. 27 regarding patient exposure to ionizing radiation in imaging procedures.

1 Sep 2009